3[1]Sivin I, Lahteenmaki P, Ranta S et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception, 1997;55(2):81～5
4[3]Gu Z, Zhu P, Luo H et al. A morphometric study on the endometrial activity of women before and after one year with LNG-IUD in situ. Contraception, 1995;52(1):57～61
5[4]Zhu P, Liu X, Luo H et al. The effect of levonorgestrel-releasing intrauterine device (20 micrograms/day) (LNG-IUD-20) on the morphological structure of human endometrium: a study of the endometrial factor Ⅷ activity in the women before and after insertion of LNG-IUD-20 by the digital image analysis. Contraception, 1995;52(1):63～8
6[6]Worret I, Arp W, Zahradnik HPet al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase Ⅲ trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology, 2001;203(1):38～44
7[7]Wildemeersch D, Dhont M, Temmerman M et al. GyneFix-LNG: preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system. Eur J Contracept ReprodHealth Care, 1999;4(1):15～9
8[8]Da Silva MO, Costa MM. Reason, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. Eur J Contracept Reprod Health Care, 1999;4(1):21～5
9[9]Paoletti AM, Pilloni M, Orru M et al. Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. Maturitas, 2002;42(2):137～47
10[10]Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause, 2002;9(3):195～207
